Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Single and Multiple Institutions: Limitations and Inferences  by Sorror, Mohamed L. et al.
LETTERS TO THE EDITORValidation of theHematopoietic
Cell Transplantation-Specific
Comorbidity Index (HCT-CI)
in Single and Multiple
Institutions: Limitations and
Inferences
We would like to comment on 2 recent studies
published in the September 2008 issue of Biology of
Blood andMarrow Transplantation. Both studies focused
on validating the discriminative capacity of the Hema-
topoietic Cell Transplantation specific-Comorbidity
Index (HCT-CI) [1] for outcomes among recipients
of allogeneic [2] and autologous [3] HCT.
The first study reviewed comorbidities among pa-
tients who were given HLA-matched related HCT
(MRD, n5 184) orHLA-matched ormismatched um-
bilical cord blood (UCB, n 5 189). Numerous condi-
tioning regimens were used that were designated
either as nonmyeloablative (NMA, n 5 223) or mye-
loablative (MA, n5 150). While assessing overall out-
comes, patients were also classified into 4 subgroups
(MRD-NMA, n 5 96; MRD-MA, n 5 88; UCB-
NMA, n 5 127; and UCB-MA, n 5 62). In the
combined cohort, HCT-CI scores of 0, 1, 2, and $3
predicted both nonrelapse mortality (NRM; 10%,
20%, 24%, and 28%, P 5 .01) and overall survival
(OS; 72%, 67%, 51%, and 48%, P 5 .01) at 2 years.
Further, in multivariate risk models, the HCT-CI
was the only independent prognostic factor for NRM
and OS, whereas age, donor source, disease risk, and
conditioning type were not. In addition, the distribu-
tion of comorbidity scores, as assigned by the HCT-
CI, was similar among the 4 subgroups of patients,
which validated its sensitivity to detect comorbidities.
Although the overall results confirmed earlier find-
ings by us [1] and others [4-10], including multi-insti-
tutional experiences [11,12], that the HCT-CI was
a strong predictor of allogeneic HCT outcomes, the
authors concluded, based on subgroup analyses, that
the HCT-CI did not predict NRM and OS as robustly
as had been suggested. Although trends for NRM and
OS were seen among 3 of the 4 subgroups, the analyses
were limited by the relatively small numbers of
patients per group. It is theoretically possible that
the HCT-CI may be more discriminatory for some
subgroups of patients than for others; however, the
most likely explanation for the subgroup findings israndom variation caused by small sample size, as well
as the heterogeneity of the patient groups with respect
to disease and other risk factors. The performance of
other comorbidity indices in these patients might
have been informative [13-15]. Uniform failure of all
indices to discriminate outcomes consistently among
the subgroups would confirm the notion that sample
sizes were too small for validation studies.
In comparison, the concurrently published Ottawa
study, despite a relatively small sample size (N5 126),
had the advantage of a homogeneous patient popula-
tion. All patients had a single diagnosis, multiple mye-
loma (MM), received autologous HCT, and were
given a single conditioning regimen. Further, the au-
thors compared the performance of the HCT-CI to
another comorbidity index, described by Charlson,
which strengthened their conclusion that indices spe-
cifically designed to assess comorbidities in the setting
of HCT could provide accurate information about
HCT-related toxicities and help decision making.
However, the finding that lung, liver, and renal
comorbidities were equally well captured by HCT-
CI and the CCI was surprising [1,4]. The HCT-CI
was designed to be more sensitive in grading those co-
morbidities by including laboratory tests, whereas the
CCI relied on clinical findings. Lack of information on
laboratory data in many patients, for example, 49% of
patients did not have pulmonary function assessment,
might have downgraded the sensitivity of the HCT-
CI and, hence, masked the true distribution of comor-
bidities in the overall cohort.
We agree that validation of the HCT-CI in differ-
ent institutions and across a broad range of transplant
conditions is important. This validation must take into
account appropriate sample sizes, adequate numbers of
tested events, accurate scoring methodology, and the
use of other comorbidity indices for comparison.
Our ongoing efforts are focused on such validation,
both retrospectively and prospectively, among large
cohorts of patients from different institutions. Large
sample sizes will allow for robust subset analyses and
appropriate adjustment of confounding factors needed
to confirm the validity and generalizability of the
HCT-CI. In the meantime, we believe that comorbid-
ity evaluation should be a vital part of pretransplant
assessment and decision making.ACKNOWLEDGMENTS
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Figure 1. Panel A: relapse-free survival (log-rank p5 0.16). Panel B:
cumulative incidence of relapse and non-relapse mortality (log-rank
p5 0.29 and p5 0.98, respectively).
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Donor CMV Serostatus Not
Predictive of Relapse in D-/R-
Pediatric HCT
To the Editor:
Cytomegalovirus (CMV) remains a major cause of
complications in hematopoietic cell transplantation
(HCT). Recipient CMV serostatus remains a predictor
of non-relapse mortality in the ganciclovir era and
seronegative recipients with a seronegative donor
